AC Immune SA (ACIU)
| Market Cap | 298.10M |
| Revenue (ttm) | 4.51M |
| Net Income (ttm) | -88.84M |
| Shares Out | 99.20M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 248,317 |
| Open | 2.900 |
| Previous Close | 2.840 |
| Day's Range | 2.900 - 3.070 |
| 52-Week Range | 1.510 - 4.000 |
| Beta | 1.63 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+232.78%) |
| Earnings Date | Apr 29, 2026 |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow A... [Read more]
Financial Performance
In 2025, AC Immune's revenue was 3.57 million, a decrease of -86.92% compared to the previous year's 27.31 million. Losses were -70.45 million, 38.4% more than in 2024.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ACIU stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 232.78% from the latest price.
News
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significa...
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's ...
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's
AC Immune SA (NASDAQ: ACIU) on Thursday released interim safety and efficacy results from the Phase 2 VacSYn trial of its anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkin...
AC Immune Transcript: Study Update
Interim phase 2 results for ACI-7104 in early Parkinson's disease show strong safety, robust antibody response, and stabilization of key biomarkers and motor symptoms, suggesting potential disease modification. Plans are underway to accelerate development and expand future trials.
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease
The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.
AC Immune Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted a robust pipeline in neurodegenerative disease, emphasizing precision medicine, active immunotherapy, and small molecule innovation. Key data readouts and clinical milestones are expected by year-end, supporting both partnered and wholly owned programs.
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small ...
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical ...
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative disea...
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active im...
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent...
AC Immune Transcript: Jefferies London Healthcare Conference 2024
A diverse pipeline is advancing with strong partnerships, robust financials, and recent clinical progress in Parkinson's and Alzheimer's programs. Key milestones are expected in 2024–2025, with a strategic focus on prevention and precision medicine.
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson's disease.
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial ...
AC Immune Transcript: Jefferies 2024 Global Healthcare Conference
A broad CNS pipeline is advancing with major partnerships, including a $2.1B deal for ACI-24.060 with Takeda and a phase IIb Tau vaccine with Johnson & Johnson. Active immunotherapies show strong safety and long-term potential, with key data readouts and internal priorities focused on Parkinson’s and inflammation assets.
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
Alzheimer's vaccine licensing deal boosts AC Immune
AC Immune S.A. shares ACIU, -1.70% jumped more than 50% premarket on Monday after the Swiss biopharma company announced a licensing deal with Takeda Pharmaceutical Co. TAK, -0.90% for an experimental ...
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for opt...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement...
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in ...
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024) Andrea Pfeifer, Ph.D., CEO to lea...
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now consider...